| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/03/2022 | -29.08% | Goldman Sachs | $4 → $2 | Maintains | Neutral |
| 07/14/2022 | 41.84% | Goldman Sachs | $5 → $4 | Maintains | Neutral |
| 04/13/2022 | 77.3% | Goldman Sachs | $9 → $5 | Maintains | Neutral |
| 01/06/2022 | 183.69% | Morgan Stanley | → $8 | Initiates Coverage On | → Equal-Weight |
| 11/02/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 08/04/2021 | 254.61% | Goldman Sachs | → $10 | Initiates Coverage On | → Neutral |
| 07/13/2021 | 360.99% | Jefferies | → $13 | Initiates Coverage On | → Buy |
Nautilus Biotechnology Questions & Answers
The latest price target for Nautilus Biotechnology (NASDAQ: NAUT) was reported by Goldman Sachs on August 3, 2022. The analyst firm set a price target for $2.00 expecting NAUT to fall to within 12 months (a possible -29.08% downside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Nautilus Biotechnology (NASDAQ: NAUT) was provided by Goldman Sachs, and Nautilus Biotechnology maintained their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nautilus Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nautilus Biotechnology was filed on August 3, 2022 so you should expect the next rating to be made available sometime around August 3, 2023.
While ratings are subjective and will change, the latest Nautilus Biotechnology (NAUT) rating was a maintained with a price target of $4.00 to $2.00. The current price Nautilus Biotechnology (NAUT) is trading at is $2.82, which is out of the analyst's predicted range.